SCHEMBL6792609

SCHEMBL6792609

Cc1cc(Nc2c3ccccc3nc3ccccc23)ccc1N

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 14/20 0.62
KMT2A Q03164 6/20 0.54
POLB P06746 4/20 0.54
RAD52 P43351 3/20 0.54
GFER P55789 2/20 0.54
MEN1 O00255 2/20 0.54
L3MBTL1 Q9Y468 2/20 0.53
NPC1 O15118 1/20 0.53
RAB9A P51151 1/20 0.53
TAAR1 Q96RJ0 1/20 0.53
KDM4E B2RXH2 3/20 0.51
MAPT P10636 2/20 0.51
NPSR1 Q6W5P4 2/20 0.51
GLA P06280 2/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
MAPK1 P28482 1/20 0.51
HTT P42858 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
MITF O75030 1/20 0.51
LMNA P02545 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6882649 0.88 KDM1A (0.62) KDM1AKMT2APOLBRAD52GFER
SCHEMBL18407155 0.86 KDM1A (0.68) KDM1AKMT2APOLBRAD52GFER
SCHEMBL17154377 0.85 KDM1A (0.62) KDM1AKMT2APOLBRAD52GFER
SCHEMBL6797100 0.80 KMT2A (0.46) KDM1AKMT2APOLBMEN1L3MBTL1
SCHEMBL18407160 0.78 L3MBTL1 (0.60) KDM1AKMT2APOLBRAD52GFER
SCHEMBL17154450 0.77 KDM1A (1.00) KDM1AKMT2APOLBRAD52GFER
SCHEMBL15673568 0.77 KDM1A (1.00) KDM1AKMT2APOLBRAD52GFER
SCHEMBL17423377 0.77 KDM1A (0.64) KDM1AKMT2APOLBMEN1RAB9A
SCHEMBL2127369 0.77 ALDH1A1 (0.70) KMT2AGFERMEN1L3MBTL1KDM4E
SCHEMBL30998047 0.77 ALDH1A1 (0.70) KMT2AGFERMEN1L3MBTL1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6821983-B2 INHIBITORS OF TOPOISOMERASE II CAN EXHIBIT ANTITUMOR ACTIVITY ACADEMIA SINICA (TW) 2004-11-23 US disclosed
US-20040198765-A1 5-(9-ACRIDINYLAMINO)-TOLUIDINE COMPOUNDS ACADEMIA SINICA (TW) 2004-10-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040198765-A1 5-(9-ACRIDINYLAMINO)-TOLUIDINE COMPOUNDS DPP9, NANP, NAT1 KDM1A 3382/4885KMT2A 2871/4885POLB 3433/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.